Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.80, $0.02 better than the analyst estimate of $0.78. Revenue for the quarter came in at $5.29 billion versus the consensus estimate of $5.28 billion.

GUIDANCE:

Boston Scientific sees FY2026 EPS of $3.43-$3.49, versus the consensus of $3.47.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.